Western Equine Encephalitis Vaccine, Inactivated


This study is designed to determine the safety and immunogenicity of WEE Vaccine Lot number 3-1-92.

Full Title of Study: “Phase 1 Study to Evaluate the Safety and Immunogenicity of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, In Healthy Adults”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2011

Detailed Description

Study Objectives: Primary: To assess safety of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, TSI-GSD 210, lot 3-1-92. Secondary: To evaluate immunogenicity of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, TSI-GSD 210, lot 3-1-92.


  • Biological: Western Equine Encephalitis Vaccine
    • Subject will be vaccinated with 0.5 mL of reconstituted WEE vaccine, inactivated, TSI-GSD 210 (Lot 3-1-92) subcutaneously in the upper outer aspect of the deltoid region.

Arms, Groups and Cohorts

  • Experimental: Vaccinated
    • Western Equine Encephalitis Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, administered in 0.5 mL doses subcutaneously in the upper outer aspect of the triceps in a 3-dose primary series (Days 0, 7, and 28) with a mandatory boost (Day 180)

Clinical Trial Outcome Measures

Primary Measures

  • Subjects Reporting Adverse Events by Vaccination and Sex
    • Time Frame: 28 days following each vaccination

Secondary Measures

  • Immunogenicity
    • Time Frame: Baseline and multiple dates throughout study
    • The primary endpoint used to measure immunogeniciyt of the WEE vaccine, the 80% plaque-reduction neautralization titer (PRNT 80), will be evaluated for subjects in the per protocol population. The secondary endpoint will be GMT, with 95% CI, of the PRNT 80 for WEE-specific antibodies at each scheduled timepoint.

Participating in This Clinical Trial

Inclusion Criteria

  • 18-55 years of age – In good health as determined by pertinent medical history, brief physical exam, vital signs, and clinical safety laboratory evaluations – Female: has a negative urine pregnancy test and is willing to use reliable form of contraception for the study duration – Negative HIV antibody screen, seronegative for HBsAg and Hepatitis C antibody – WEE, EEE, VEE, and CHIK PRNT80<1:10 – Ability to comprehend abnd a willingness to sign an informed consent, which includes the HIPAA and a separate HIV consent form – Be willing to comply with all follow-up visits, testing, and AE reporting Exclusion Criteria:
  • Participant in the USAMRIID SIP – Receipt of any other vaccine or investigational; drug within 30 days prior to study entry – Anticipates receipt of other vaccines for the duration of the study (influenza vaccination will be permitted but not within 28 days of WEE vaccination – Acute of chronic medical conditions, medications, or dietary supplements that, in the PI's opinion, would impair the subject's ability to respond to vaccination – Hypersensitivity to any vaccine – Allergic to any vaccine component: Human serum albumin, Neomycin – Receipt of or anticipates receipt of blood products during the study – Female: Pregnant or breastfeeding – Clinically significant abnormal laboratory tests (generally greater than or equl to 2 times the upper limit of normal as determined by the PI)
  • Gender Eligibility: All

    Minimum Age: 18 Years

    Maximum Age: 55 Years

    Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

    Investigator Details

    • Lead Sponsor
      • U.S. Army Medical Research and Development Command
    • Provider of Information About this Clinical Study
      • Sponsor
    • Overall Official(s)
      • Ronald B Reisler, MD, Principal Investigator, USAMRIID Medical Division

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.